Telix Pharmaceuticals 2023 J.P. Morgan Healthcare Conference

Telix Pharmaceuticals presented at the J.P. Morgan Healthcare Conference in January 2023, showcasing its commercial-stage radiopharmaceutical portfolio including the FDA-approved Illuccix for prostate cancer imaging. The company highlighted its industry-leading theranostic pipeline with over 20 active clinical studies, US$100.4M in U.S. sales since April 2022 launch, and plans for expanded manufacturing capacity.